Cost Effectiveness of Cetuximab and Panitumumab for First-Line RAS WT Metastatic Colorecal Cancer
May 1, 2016, 00:00 AM
10.1016/j.jval.2016.03.1612
https://www.valueinhealthjournal.com/article/S1098-3015(16)01680-6/fulltext
Section Title :
Cancer - Cost Studies
Section Order :
334
First Page :
A154
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)01680-6&doi=10.1016/j.jval.2016.03.1612